Quantcast

Latest Telik Inc. Stories

2010-10-26 13:57:00

PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today that Telintra (Ezatiostat HCl), the company's lead therapeutic product candidate, has been selected by Windhover Information and its advisors as one of "The Top 10 Most Interesting Oncology Projects to Watch." Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. The company has been invited to present at...

2010-08-06 15:05:00

PALO ALTO, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $4.9 million, or $0.09 per share, for the second quarter ended June 30, 2010, compared with a net loss of $5.7 million, or $0.11 per share, for the comparable period in 2009. For the quarter ended June 30, 2010, total operating costs and expenses were $5.0 million, compared with $6.3 million in the 2009 second quarter. Operating expenses in the 2010 second quarter included...

2010-07-12 13:25:00

PALO ALTO, Calif., July 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and...

2010-06-21 13:33:00

PALO ALTO, Calif., June 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a case report by Quddus et al., Oral Ezatiostat HCl (Telintra) and Myelodysplastic Syndrome: A case report of sustained hematologic response following an abbreviated exposure. Journal of Hematology & Oncology 2010, 3:16. This case report describes a patient who experienced a sustained hematologic response in all three blood cell lines continuing for over a year, after an...

2010-06-08 08:00:00

PALO ALTO, Calif., June 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 2 multicenter trial of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with an International Prognostic System Score (IPSS) low to intermediate-1 risk myelodysplastic syndrome (MDS). The primary objective of the study was to determine the Hematologic Improvement (HI) rate according to the International Working Group criteria (IWG, 2006). Since MDS...

2010-06-02 15:05:00

PALO ALTO, Calif., June 2 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide corporate overviews at the following investment conferences: Jefferies 2010 Global Life Sciences Conference, New York; Wednesday, June 9, 2010 at 1:30 p.m. EDT (10:30 a.m. PDT) 9th Annual Needham Healthcare Conference, New York; Thursday, June 10, 2010 at 2:00 p.m. EDT (11:00 a.m. PDT) A live and archived webcast of the Needham presentation will be...

2010-05-06 15:05:00

PALO ALTO, Calif., May 6 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2010. The net loss for the quarter ended March 31, 2010 was $5.3 million, or $0.10 per share, compared with a net loss of $7.7 million, or $0.14 per share, for the same period in 2009. Total research and development expenses (R&D) in the first quarter of 2010 were $2.8 million, compared to $4.0 million for the same period in 2009. The...

2010-04-22 19:47:00

PALO ALTO, Calif., April 22 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that it has received from The Nasdaq Stock Market notification that Telik has regained compliance with the minimum bid price rule for continued listing on The Nasdaq Capital Market because the bid price of Telik's common stock has closed at $1.00 per share or greater for at least 10 consecutive business days. About Telik Telik, Inc. of Palo Alto, CA, is a clinical stage drug development...

2010-02-25 15:05:00

PALO ALTO, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $4.2 million, or $0.08 per share, for the three months ended December 31, 2009, compared with a net loss of $0.4 million, or $0.01 per share, for the comparable period in 2008. The results for the three months ended December 31, 2008 included an unrealized net gain of $4.6 million due to changes in fair value of investments and related rights. For the quarter ended December 31, 2009,...

2010-02-01 15:05:00

PALO ALTO, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the 12th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 9 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related